Axsome Therapeutics announced presentations of data from its CNS portfolio at the 2023 U.S. Psych Congress in Nashville September 6-10. The presentations will include eight posters with data and analyses which examine the effects of Auvelity on sleep quality and cognitive and physical functioning in patients with major depressive disorder, and the effects of Sunosi on cognition in patients with excessive daytime sleepiness due to obstructive sleep apnea. Five of the eight posters are finalists under consideration for the Psych Congress Poster Awards. Key highlights include: data examining durability of efficacy and tolerability with long-term – up to 12 months – treatment with Auvelity in patients with MDD, including measures of depressive symptoms, anxiety, and cognitive and physical functioning; data examining the effect of Auvelity on depression-related disability, and patient-reported measures of insomnia in patients with MDD; data examining treatment effect sizes of Sunosi in patients with EDS associated with narcolepsy and OSA; data examining the effects of Sunosi on cognition in patients with EDS and OSA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
- Biotech Alert: Searches spiking for these stocks today
- Axsome Therapeutics price target raised to $100 from $95 at Mizuho
- DraftKings upgraded, Home Depot downgraded: Wall Street’s top analyst calls
- Axsome Therapeutics price target lowered to $180 from $190 at H.C. Wainwright